Steroid shots and blood treatment don't work on the same schedule

A steroid may help sooner but often wears off

A steroid shot can ease soreness within days for some people. Its clearest average help comes early, but it doesn't always last.

A few easier weeks may let you return to gentle exercise. Repeats aren't automatic, because they may help less and can raise safety concerns.

Tell the doctor how long the last shot worked and whether each round helped less. That talk should cover cartilage, blood sugar, and any plans for surgery.

Blood treatment takes more time and costs more

Some studies found relief after more time, but the results don't all agree. One careful trial found PRP no better than a salt-water shot with no active medicine.

That mixed record matters because you'll usually pay more, and coverage may not be available. At QC Kinetix, regenerative treatments mean you'll meet its medical provider, who checks your knee and history, then prepares concentrated PRP and performs the non-surgical procedure there.

Your goal and your budget belong in the choice

Ask when relief may begin and when it often fades. Before agreeing, get the total cost, likely visits, and expense if the knee doesn't improve.

Neither choice can fix every cause of knee soreness, and neither works for everyone. A fair talk includes home care, waiting, and surgery when those choices fit better.

Write down the procedure date and how your walking changes afterward. Don't judge the result from one unusually easy morning.

Sources

1. The 2015 Cochrane review of 27 trials (1,767 participants) found intra-articular corticosteroid better than sham for knee OA pain (SMD -0.40, 95% CI -0.58 to -0.22; NNTB 8), but the benefit decayed with time: moderate at 1-2 weeks, small at 13 weeks, and no evidence of any effect at 26 weeks. All outcomes were graded LOW quality.

   Jüni P, et al. — Intra-articular corticosteroid for knee osteoarthritis.. Cochrane Database Syst Rev, 2015. DOI: 10.1002/14651858.CD005328.pub3.

2. In a 2-year double-blind RCT of 140 patients with symptomatic knee OA and ultrasound synovitis, 40 mg intra-articular triamcinolone every 12 weeks produced significantly greater cartilage volume loss than saline (index compartment cartilage thickness change -0.21 mm vs -0.10 mm; between-group difference -0.11 mm, 95% CI -0.20 to -0.03) with no significant difference in knee pain.

   McAlindon TE, et al. — Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.. JAMA, 2017. DOI: 10.1001/jama.2017.5283.

3. The RESTORE randomized trial (288 participants, leukocyte-poor PRP, 3 weekly injections) found no significant difference from saline placebo at 12 months in knee pain (-2.1 vs -1.8 points; difference -0.4, 95% CI -0.9 to 0.2) or in medial tibial cartilage volume (-1.4% vs -1.2%), with 29 of 31 secondary outcomes also showing no between-group difference.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

4. A 2024 network meta-analysis of 48 studies (9,338 knees) at minimum 6-month follow-up ranked PRP first for pain and function (SUCRA 91.5), then BMAC (76.5) and hyaluronic acid (53.1), with corticosteroid (15.2) barely above placebo (13.7) at that time point.

   Jawanda H, et al. — Platelet-Rich Plasma, Bone Marrow Aspirate Concentrate, and Hyaluronic Acid Injections Outperform Corticosteroids in Pain and Function Scores at a Minimum of 6 Months as Intra-Articular Injections for Knee Osteoarthritis: A Systematic Review and Network Meta-analysis.. Arthroscopy, 2024. DOI: 10.1016/j.arthro.2024.01.037.

5. A meta-analysis of eight low-risk-of-bias studies (648 patients) found PRP significantly better than corticosteroid for pain, stiffness and function at 3, 6 and 9 months, with the largest effects at 6 months (SMD -0.78) and 9 months (SMD -1.63), and found triple PRP injections superior to single injections over 12 months.

   McLarnon M, et al. — Intra-articular platelet-rich plasma injections versus intra-articular corticosteroid injections for symptomatic management of knee osteoarthritis: systematic review and meta-analysis.. BMC Musculoskelet Disord, 2021. DOI: 10.1186/s12891-021-04308-3.

6. A network meta-analysis of 43 trials (5,554 patients) reached the OPPOSITE ranking to several PRP-favourable reviews: steroids ranked most likely to be effective for pain and function, with adipose MSC and multiple PRP injections ranked least likely, and steroids and hyaluronic acid showed lower adverse-event rates than placebo.

   Han SB, et al. — Intra-Articular Injections of Hyaluronic Acid or Steroids Associated With Better Outcomes Than Platelet-Rich Plasma, Adipose Mesenchymal Stromal Cells, or Placebo in Knee Osteoarthritis: A Network Meta-analysis.. Arthroscopy, 2021. DOI: 10.1016/j.arthro.2020.03.041.

7. A meta-analysis of 10 RCTs of RECURRENT intra-articular corticosteroid injections (2-8 injections per patient) found they often gave inferior or non-superior relief compared with hyaluronic acid, PRP, saline or orgotein at 3 months and beyond, and no benefit over placebo in pain or function at 12-24 months.

   Donovan RL, et al. — Effects of recurrent intra-articular corticosteroid injections for osteoarthritis at 3 months and beyond: a systematic review and meta-analysis in comparison to other injectables.. Osteoarthritis Cartilage, 2022. DOI: 10.1016/j.joca.2022.07.011.

8. In the Osteoarthritis Initiative cohort (684 propensity-matched participants), knees whose owners started intra-articular corticosteroids had radiographic OA worsening at 21.7 per 100 person-years versus 7.1 in comparators; the hazard ratio for Kellgren-Lawrence worsening was 3.02 for initiation, higher still for continuous use.

   Zeng C, et al. — Intra-articular corticosteroids and the risk of knee osteoarthritis progression: results from the Osteoarthritis Initiative.. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.01.007.

9. A 2024 systematic review of eight randomized trials (937 patients) found BMAC improved pain and function from baseline and beat hyaluronic acid on pain at 6 and 12 months, but the differences did NOT exceed the minimal clinically important difference, and no significant differences emerged against other injectables.

   Han JH, et al. — Bone Marrow Aspirate Concentrate Injections for the Treatment of Knee Osteoarthritis: A Systematic Review of Randomized Controlled Trials.. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241296555.

10. A systematic review of eight studies (299 knees, mean follow-up 12.9 months) found BMAC improved 34 of 36 patient-reported outcomes from baseline, but all three comparative studies failed to show BMAC superior to other biologic injections or to placebo - a finding the authors weigh against its high cost.

    Keeling LE, et al. — Bone Marrow Aspirate Concentrate for the Treatment of Knee Osteoarthritis: A Systematic Review.. Am J Sports Med, 2022. DOI: 10.1177/03635465211018837.

11. The 2025 Cochrane living review of stem cell injections for knee OA (25 trials, 1,341 participants) found stem cell injection MAY slightly improve pain and function up to six months versus placebo (pain 1.2 points better on a 0-10 scale; function 14.2 points better on 0-100), but rated the evidence LOW certainty for both, downgraded for indirectness and suspected publication bias, with up to three larger RCTs withdrawn before reporting results.

    Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database Syst Rev, 2025. DOI: 10.1002/14651858.CD013342.pub2.

12. FDA's HCT/P guidance sets out the minimal-manipulation and homologous-use criteria that decide whether a human cell or tissue product is regulated solely under 21 CFR Part 1271 (section 361) or requires a biologics licence; cell-based orthopaedic injections that fall outside those criteria are unapproved drugs and biological products, and no cell-based product is FDA-approved to treat osteoarthritis.

    U.S. Food and Drug Administration — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and FDA Staff. U.S. Food and Drug Administration, 2020.